The share

SpectraCure’s share is listed on the Nasdaq First North Growth Market under the short name SPEC and is traded via banks and stockbrokers. SpectraCure is a record company and its shares are registered in electronic form with Euroclear Sweden AB, where its share register is also kept. All shares are of the same type, have an equal right to a share in the Company’s assets and profits and have the same voting value. All shares are issued and fully paid up.

Shares AK
Number of shares: 97,131,608
ISIN: SE0007158118

The company does not currently have any outstanding warrants.

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope